Edit
Abscint: Molecular imaging in Oncology, Immunology and Cardiology
https://abscint.com/Last activity: 26.09.2023
Active
Company in Clinical Stage that develops platform production processes allowing fast production of cold kits for new applications/sdAbs.
Location: Belgium, Brussels-Capital, Ganshoren
Total raised: $3.18M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2023 | - | $3.18M | Qbic Fund |
Mentions in press and media 2
| Date | Title | Description |
| 26.09.2023 | ABSCINT raises € 3 million round to initiate Phase II Clinical Trials | Brussels, Liège, September 25, 2023 - ABSCINT has secured EUR 3 million for its technology platform that enables rapid targeting and visualisation of specific molecular markers throughout the entire body via a PET scan. ABSCINT is actively ... |
| 05.12.2022 | ABSCINT raises new financing round | Brussels, Liège, December 5, 2022. ABSCINT is a clinical stage molecular imaging company that develops radiopharmaceutical diagnostics to guide patients and doctors to the right treatment at the right time. Its technology platform relies on... |